Vulvar and pelvic-origin lower-extremity varicose veins: A survey of current evaluation and management Authors: Peyton M. Cramer, Kimberly Scherer, Ronald S. Winokur, Neil Khilnani Published: 2027 ABSTRACT ObjectiveThe primary objective is to assess current practice for evaluating and managing vulvar (V3a) and pelvic origin lower-extremity varicose veins (V3b) to inform future research priorities and guideline development.MethodsAn electronic survey was internationally distributed to vascular specialists to assess the current state of pelvic venous disorder care. The 51-question survey was administered using the Qualtrics platform and distributed through medical society forums, mailing lists of the international vascular meetings, and direct distributions. The survey was open from June to July 2024, requiring approximately 10 to 15 minutes to complete. Background information included respondent age, gender, training experience, primary medical specialty, practice type, and practice location, with responses remaining anonymous. The survey included five sections, with evaluation and management of women with V3 disease being the focus of this paper. This study was reviewed by the Institutional Review Board and qualified for exemption.ResultsThe majority of survey respondents were vascular surgeons (47%) and interventional radiologists (38%) from the United States (43%), Asia (17%), and Europe (16%). A total of 194 respondents reported treating women with extra-pelvic varices of pelvic origin and completed this portion of the survey. For women with V3a and V3b diseases, 46% used the Symptoms-Varices-Pathophysiology classification tool as a part of the clinical assessment before treatment. The preferred imaging modality before intervention is duplex ultrasound of the lower extremity (61%-81%) and pelvic ultrasound (36%-47%). In women without pelvic pain, a “top-down” pelvic embolization first approach is used by 47% treating V3a and 42% treating V3b, and a “bottom-up” direct injection sclerosis was used by the remainder. The technical approach to pelvic embolization when choosing a “top-down” approach is variable, with the majority using foam sclerosant for pelvic venous embolization (69%), as well as for vulvar or lower-extremity varicose veins (84%). The majority prefer both imaging and clinical follow-up, with 75% using a clinical outcome tool postprocedurally. The management of persistent or recurrent symptoms after treatment is variable, ranging from conservative care (8%), retreating with the same approach (10%-29%), or using a different approach (if “top down” initially, then “bottom up” or if “bottom up” initially, then “top down”; 22%-27%).ConclusionsThis survey demonstrates the significant diagnostic and therapeutic heterogeneity of V3a and V3b in the absence of pelvic pain, including equipoise for top-down and bottom-up management. This heterogeneity demonstrates that significant evidence gaps exist, and highlights the need for comparative outcomes research to clarify them. Article Highlights •Type of Research: Single-center prospective observational study•Key Findings: An international survey of 194 vascular specialists demonstrates marked heterogeneity in the evaluation, classification, and management of women with vulvar and pelvic-origin lower-extremity varicose veins. Diagnostic imaging strategies, use of standardized clinical and outcome measures, and treatment sequencing vary widely, with heterogeneous approaches to managing persistent symptoms after treatment.•Take Home message: This survey demonstrates significant diagnostic and therapeutic heterogeneity in the evaluation and management of vulvar and pelvic venous disorders in the absence of pelvic pain, including equipoise between top-down and bottom-up management. Article Highlights •Type of Research: Single-center prospective observational study•Key Findings: An international survey of 194 vascular specialists demonstrates marked heterogeneity in the evaluation, classification, and management of women with vulvar and pelvic-origin lower-extremity varicose veins. Diagnostic imaging strategies, use of standardized clinical and outcome measures, and treatment sequencing vary widely, with heterogeneous approaches to managing persistent symptoms after treatment.•Take Home message: This survey demonstrates significant diagnostic and therapeutic heterogeneity in the evaluation and management of vulvar and pelvic venous disorders in the absence of pelvic pain, including equipoise between top-down and bottom-up management. •Type of Research: Single-center prospective observational study Type of Research: Single-center prospective observational study •Key Findings: An international survey of 194 vascular specialists demonstrates marked heterogeneity in the evaluation, classification, and management of women with vulvar and pelvic-origin lower-extremity varicose veins. Diagnostic imaging strategies, use of standardized clinical and outcome measures, and treatment sequencing vary widely, with heterogeneous approaches to managing persistent symptoms after treatment. Key Findings: An international survey of 194 vascular specialists demonstrates marked heterogeneity in the evaluation, classification, and management of women with vulvar and pelvic-origin lower-extremity varicose veins. Diagnostic imaging strategies, use of standardized clinical and outcome measures, and treatment sequencing vary widely, with heterogeneous approaches to managing persistent symptoms after treatment. •Take Home message: This survey demonstrates significant diagnostic and therapeutic heterogeneity in the evaluation and management of vulvar and pelvic venous disorders in the absence of pelvic pain, including equipoise between top-down and bottom-up management. Take Home message: This survey demonstrates significant diagnostic and therapeutic heterogeneity in the evaluation and management of vulvar and pelvic venous disorders in the absence of pelvic pain, including equipoise between top-down and bottom-up management. Pelvic venous disorders (PeVDs) are conditions that result from venous hypertension within the pelvis. They can be symptomatic or asymptomatic and may be related to primary reflux of the ovarian or internal iliac veins or secondary reflux of these veins due to compensated left renal or common iliac vein obstruction. There are four clinical presentations of PeVD, with venous origin chronic pelvic pain (VO-CPP) being the most frequently discussed. The other presentations are pelvic-origin vulvar and lower-extremity varicose veins (V3a and V3b, respectively); left flank pain or hematuria from uncompensated left renal vein obstruction; and lower-extremity venous claudication or swelling from uncompensated iliac vein obstruction.1 Previously thought of as different “syndromes,” these are now appreciated to have interconnected underlying pathophysiology, presenting with a spectrum of signs and symptoms that are based on how the venous hypertension is distributed.2 The PeVD literature has been criticized due to heterogeneous patient selection, treatment strategies, and outcome assessments. The primary objective of this study was to evaluate current practices for evaluating and managing women with V3a and V3b without pelvic pain to inform future research priorities and guideline development, as well as optimization of treatment utilization. A secondary objective was to understand treatment decision heterogeneity as it relates to the specialty and geographical location of the treating physician. An additional objective was to understand how outcomes are assessed and how persistent symptoms after venous interventions are managed in this subset of PeVDs. Methods This study is part of an international survey examining current practice patterns across the spectrum of PeVD. The web-based survey used the Qualtrics platform with no identifying respondent information collected. The 51-question survey was open from June to July 2024, requiring approximately 10 to 15 minutes to complete by the practitioner. The survey included both single-select and multiple-select multiple-choice questions, as well as free-text style questions. The survey was internationally distributed using medical society forums, contact lists of the international vascular meetings, and direct distributions. Not all respondents answered every question; denominators are provided for each result. The survey consisted of five sections, including participant background information; evaluation and management of VO-CPP; pelvic-origin lower-extremity varicose veins; vulvar varicose veins; and iliac and renal vein obstruction. The survey questions were developed by the authors, focusing on the areas of PeVD with known heterogeneous practice patterns. This study focused on participant background information and the 16 questions addressing pelvic-origin lower-extremity and vulvar varicose veins in women without pelvic pain. This study was reviewed by the Institutional Review Board (Protocol No. 24-0126943) and qualified for exemption. Results The groups that facilitated survey distribution are listed in Table I. Respondent demographics are depicted in Table II. There were 360 total respondents, with 317 indicating that they treat women with PeVD as a source of chronic pelvic pain and/or lower-extremity or vulvar varicose veins. Of these, 194 respondents treat women with extra-pelvic varices of pelvic origin in the lower extremities and/or vulva.Table ISurvey distribution facilitatorsSociety of Interventional RadiologyAmerican Vein and Lymphatic SocietyAmerican Venous ForumVenous SymposiumKorean Society of Interventional RadiologyCardiovascular and Interventional Radiological Society of EuropeVascular Interventional Advances (VIVA) FoundationIrish Society of Interventional RadiologyKorean Society of Vascular and Endovascular SurgeryDutch College of PhlebologyInternational Union of PhlebologyFrench Society of Vascular and Endovascular SurgeryIR Community in BrazilIR Community in SpainIR Community in Australia/OceaniaTable IIRespondent demographicsDemographicsResponsesMean age (n = 245)59Male gender (n = 269)206 (77)Post-training practicing vascular care, years (n = 271) <542 (15) 6-1051 (19) 11-1539 (14) >15139 (51)Current practice type (n = 269) Academic71 (26) Private105 (39) Hybrid85 (32) Other8 (3)Current practice location (n = 259) The United States112 (43) Asia43 (17) Africa7 (3) North America (outside of the United States)22 (9) South America31 (12) Europe43 (16) Australia2 (1)Primary discipline (n = 271) Interventional radiology102 (38) Vascular surgery127 (47) Cardiology4 (2) Phlebology12 (4) Angiology5 (2) Vascular medicine4 (2) Others17 (6)Categorical data are shown as number (%). Table ISurvey distribution facilitatorsSociety of Interventional RadiologyAmerican Vein and Lymphatic SocietyAmerican Venous ForumVenous SymposiumKorean Society of Interventional RadiologyCardiovascular and Interventional Radiological Society of EuropeVascular Interventional Advances (VIVA) FoundationIrish Society of Interventional RadiologyKorean Society of Vascular and Endovascular SurgeryDutch College of PhlebologyInternational Union of PhlebologyFrench Society of Vascular and Endovascular SurgeryIR Community in BrazilIR Community in SpainIR Community in Australia/Oceania Survey distribution facilitators Table IIRespondent demographicsDemographicsResponsesMean age (n = 245)59Male gender (n = 269)206 (77)Post-training practicing vascular care, years (n = 271) <542 (15) 6-1051 (19) 11-1539 (14) >15139 (51)Current practice type (n = 269) Academic71 (26) Private105 (39) Hybrid85 (32) Other8 (3)Current practice location (n = 259) The United States112 (43) Asia43 (17) Africa7 (3) North America (outside of the United States)22 (9) South America31 (12) Europe43 (16) Australia2 (1)Primary discipline (n = 271) Interventional radiology102 (38) Vascular surgery127 (47) Cardiology4 (2) Phlebology12 (4) Angiology5 (2) Vascular medicine4 (2) Others17 (6)Categorical data are shown as number (%). Respondent demographics Categorical data are shown as number (%). Pretreatment assessment and classification Clinical assessment tools used before treating pelvic-origin varicose veins included a visual analogue scale (51%, 81/160), a quality-of-life (QoL) tool for lower-extremity varicose veins (33%, 52/160), a generic QoL questionnaire (14%, 23/160), other instruments (8%, 14/160), or none (24%, 38/160). Free-text responses included Venous Clinical Severity Score (VCSS), Clinical-Etiology-Anatomy-Pathophysiology (CEAP) classification, and International Pelvic Pain Society (IPPS) tools. In total, 46% (74/160) of respondents routinely record the Symptoms-Varices-Pathophysiology classification in the health record before treating women with V3a and V3b venous disease. Imaging evaluation Preprocedural imaging for V3a included lower-extremity duplex (61%, 99/161), transabdominal pelvic ultrasound (US; 47%, 76/161), vulvar and/or escape-point US (42%, 68/161), transvaginal pelvic US (39%, 62/161), computed tomography (CT; 33%, 53/161), magnetic resonance (MR; 20%, 32/161), or none (1%, 2/161). Preprocedural imaging for V3b typically used included lower-extremity duplex (81%, 129/160), transabdominal pelvic US (46%, 74/160), transvaginal US (36%, 57/160), vulvar and/or escape-point-directed US (36%, 57/160), CT (34%, 54/160), MR (23%, 36/160), or none (1%, 1/160). Initial treatment strategy A “top-down” approach focuses on eliminating the pelvic veins as the first step in treating pelvic origin extra-pelvic varicose veins and related symptoms. V3a and V3b in the absence of pelvic pain are treated with a “top-down” approach by 47% (76/161) and 42% (68/161) of respondents, respectively. The top-down approach for V3a was used by 50% (29/58) of interventional radiologists and 46% (47/103) of non-interventional radiologists, as well as by 48% (37/77) of practitioners in the United States and 46% (39/84) of practitioners outside of the United States. The top-down approach for V3b was used by 43% (25/58) of interventional radiologists and 42% (43/103) of non-interventional radiologists, as well as by 48% (37/77) of practitioners in the United States and 46% (39/84) of practitioners outside of the United States. Venography techniques are widespread when assessing varicose veins of pelvic origin, with 36% (58/161) assessing both ovarian and iliac veins, 29% (46/161) depending on preprocedural imaging findings, and the remaining approaches variable, including one ovarian vein (3%, 4/161), both ovarian veins (3%, 5/161), one internal iliac vein (1%, 2/161), or both internal iliac veins (11%, 17/161). The management of left renal vein obstruction was not explicitly addressed in this question and is not included in the current analysis. Balloon occlusion venography was routinely used by 29% (47/160) of respondents, specifically in the internal iliac vein (15%, 24/160), the ovarian vein (6%, 9/160), and for all studied veins (9%, 14/160) when using a top-down approach. Technical approach to pelvic intervention When both iliac vein compression/obstruction and pelvic/ovarian vein reflux were identified, responses were widely distributed among all possible strategies, with no dominant approach. This further highlights the absence of an agreed disease hierarchy for reflux and obstruction in patients with extra-pelvic varices. When treating V3a or V3b, if both significant iliac vein compression and pelvic reflux are visualized, 37% (59/157) treat compression first, 24% (38/158) treat reflux first, 9% (14/158) treat both compression and reflux simultaneously, and 30% (47/158) used a situation-dependent approach. Typical embolic agents used for pelvic venous embolization are depicted in Fig 1. In total, 18% (29/161) did not use embolization to treat women with these issues. Fig 2 depicts the typical approach when pelvic venous embolization is not performed and a “bottom-up” approach is taken.Fig 1Preferred embolic agents for “top-down” approach with pelvic venous embolization (n = 160).Fig 2Management with a “bottom-up” approach when pelvic embolization is not performed (n = 160). Preferred embolic agents for “top-down” approach with pelvic venous embolization (n = 160). Management with a “bottom-up” approach when pelvic embolization is not performed (n = 160). Follow-up and outcome assessment Formal outcome assessment was inconsistent. Postprocedural follow-up most commonly included both imaging and clinical follow-up (65%, 105/161), with clinical follow-up (32%, 52/161) or imaging follow-up (3%, 4/161) alone less frequent. The timing and frequency of follow-up was not clarified in the survey. Outcome instruments used to assess patients after the treatment of V3b included a visual analogue scale (48%, 76/160), lower-extremity varicose veins QoL tool (33%, 53/160), generic QoL instrument (15%, 24/160), none (25%, 40/160), and other patient-reported outcome tools (9%, 14/160), including VCSS, CEAP, and IPPS. Management of persistent or recurrent symptoms When there are persistent or recurrent symptoms 6 months after the initial intervention, practitioners in the United States provided conservative care (5%, 4/76), retreatment with direct injection (30%, 23/76), retreatment with embolization (4%, 3/76), if originally “top-down” approach then switch to a “bottom-up” direct injection sclerotherapy (26%, 20/76), and if originally “bottom-up” approach then switch to a “top-down” pelvic venography and embolization (27%, 21/76), or other (7%, 5/76). Practitioners outside the United States provided conservative care (10%, 8/82), retreatment with direct injection sclerotherapy (28%, 23/82), retreatment with embolization (15%, 12/82), if originally “top-down” approach then switch to a “bottom-up” direct injection sclerotherapy (18%, 15/82), and if originally “bottom-up” approach then switch to a “top-down” pelvic venography and embolization (27%, 22/82), or other (2%, 2/82). When there are persistent or recurrent symptoms 6 months after intervention, interventional radiologists provided conservative care (2%, 1/57), retreatment with direct injection sclerotherapy (19%, 11/57), retreatment with embolization (9%, 5/57), if originally “top-down” approach then switch to a “bottom-up” direct injection sclerotherapy (37%, 21/57), and if originally “bottom-up” approach then switch to a “top-down” pelvic venography and embolization (26%, 15/57), or other (7%, 4/57). Within noninterventional radiology specialties, practitioners provided conservative care (11%, 11/101), retreatment with direct injection sclerotherapy (35%, 35/101), retreatment with embolization (10%, 10/101), if originally “top-down” approach then switch to a “bottom-up” direct injection sclerotherapy (14%, 14/101), and if originally “bottom-up” approach then switch to a “top-down” pelvic venography and embolization (28%, 28/101), or other (3%, 3/101). Discussion There is substantial international heterogeneity in the evaluation and management of pelvic-origin lower extremity (V3b) and vulvar (V3a) varicose veins. Treatment sequencing is nearly evenly divided between top-down (pelvic embolization and/or stenting first) and bottom-up (direct treatment of extra-pelvic veins first) strategies in the absence of pelvic pain. This near-equal use of top-down and bottom-up strategies may indicate that either approach is reasonable in appropriately selected patients, rather than that a single preferred treatment strategy exists. However, the limited comparative evidence does not currently define which patients are most likely to benefit from each approach or whether the strategies differ in effectiveness, durability, need for reintervention, or procedural burden. These findings therefore support prospective comparative studies focused not only on whether one approach is superior, but also on identifying the clinical and anatomic factors that should guide treatment selection. Treatment is currently based on competing philosophies, but not grounded in strong evidence.3 The rationale for a top-down approach, treating pelvic venous reflux first, is reported to eliminate the source of varices and prevent recurrence by decreasing venous hypertension in the pelvic reservoir.4 The rationale for a bottom-up approach is to treat symptomatic lower-extremity or vulvar varices, addressing the patient's most visible or symptomatic disease and avoid pelvic intervention unless necessary.5 There has been anecdotal successful durability of the bottom-up approach and potentially eliminates the need for multiple procedures. The near-equal distribution of these strategies demonstrates that substantially different treatment pathways are currently being used without comparative evidence sufficient to guide patient selection. Thus, prospective comparative studies remain important to determine the relative effectiveness of each strategy and which patients are best suited to each approach.6 A recently published Society of Interventional Radiology practice guidance document recommends an initial “bottom-up” treatment approach for symptomatic V3a/b patients without clinically significant VO-CPP; however, this recommendation is an evidence-informed practice rather than a conclusion supported by comparative treatment data, and treatment should be individualized according to the patient’s clinical presentation. It also recommends venous embolization as a reasonable first step for such women who also have clinically important VO-CPP, but at the same time acknowledges a lack of strong evidence to guide management of these conditions.7 There is uncertainty in managing patients with both pelvic venous reflux and obstruction in V3a/b patients, and no evidence-based strategy for simultaneous or sequential timing of treatments when both conditions are present. Clinicians are split between treating compression first, treating reflux first, or treating both simultaneously, highlighting a critical knowledge gap regarding pathophysiology and the need to define disease hierarchy. The heterogeneity observed in the reintervention strategies of persistent or recurrent V3a and V3b disease again highlights the uncertainty regarding therapeutic hierarchy rather than disagreement about causality. Pelvic venous hypertension is widely recognized as the underlying driver of reflux leading to the varicose veins; however, it remains unclear whether elimination of the extrapelvic venous reservoir alone may be sufficient to achieve durable elimination of these veins, or whether direct treatment of the pelvic reflux source is required first. Anecdotal experience suggests that a “bottom-up” strategy may provide adequate relief in selected patients. Conversely, existing data on pelvic embolization does not consistently demonstrate complete resolution of vulvar or lower-extremity varices.8 When pelvic embolization is selected for V3a and V3b disease, the relevant refluxing pelvic tributaries may be important because V3a/b varices can arise through specific pelvic escape points rather than solely through ovarian vein reflux. Thus, ovarian vein embolization alone would not necessarily be expected to eliminate all pelvic-origin extra-pelvic varices.9 Given that V3a/b veins are almost exclusively derived from posterior division tributary reflux from internal iliac veins through pelvic floor escape points, isolated ovarian vein embolization will be unlikely to eliminate V3a/b unless the pelvic escape route includes a refluxing round ligament vein (RLV). The RLV is sourced from the ovarian venous plexus, leading to anterior vulva and or inguinally sourced thigh veins from the inguinal escape point. Therefore, pelvic embolization needs to be tailored to the location of V3a and V3b varicosities that exist and typically requires selectively embolizing the relevant pudendal, gluteal, or obturator veins to and across their escape points to be successful (similarly to the RLV). There is also substantial variation in the diagnostic evaluation of these conditions. Although most respondents perform lower-extremity duplex, pelvic-focused imaging strategies vary widely. Transvaginal US, transabdominal US, escape-point imaging, CT, and MR are all used, but inconsistently. The implication is that there is no agreed-upon diagnostic algorithm for identifying pelvic sources of extrapelvic varices, which likely contributes to inconsistent patient selection for the variety of imaging modalities in practice. Our data shows that the Symptoms-Varices-Pathophysiology classification is not universally used. A significant proportion of clinicians use no formal outcome measure before or after treatment and when outcomes are measured, tools vary significantly (such as visual analog scale, venous QoL instruments, and generic QoL). The heterogeneity in outcome assessment use mirrors the current literature and explains why existing studies are difficult to compare, therefore making pooled analyses challenging. This underscores the need for standardized clinical and imaging criteria and use of multispecialty prescribed core outcome sets, which include validated patient-reported outcome measures relevant to this population. This will help optimize patient categorization and facilitate optimization of treatment strategies. Currently there is no consensus developed core outcome set for these patients.10 Developing and requiring the use of such a set would be helpful to standardize patient data collection, report outcomes, and pool data to optimize treatment. The study results raise clinical and research implications for patients with V3a and V3b, showing that patients may receive fundamentally different care depending on provider specialty or region. This lack of standardization may lead to both overtreatment and undertreatment. Our data supports development of standardized diagnostic pathways, adoption and utilization of uniform classification systems, as well as the creation and use of core outcome sets in research studies so that all future literature and treatment strategies have all of the important outcomes reported, to allow pooling of data for systematic review and meta-analysis. Our results also highlight the need for prospective trials comparing top-down vs bottom-up strategies in this population. Studies clarifying the relative value of treating iliac compression and/or pelvic venous insufficiency, specifically for V3a/b, will also be useful. Several limitations exist in this study. The survey was shared via societies and groups that not all clinicians active in caring for these patients are members of, leading to potential sampling bias, including specialty and geographic response imbalance. Society-specific response rates could not be calculated because the survey was distributed through multiple overlapping societies, and all responses remained anonymous to encourage honest responses and in accordance with our Institutional Review Board-approved protocol. As an international survey, there are inherent cultural influences biasing the results. Regional practice environments, training, health care systems, resource availability, and local treatment norms may have contributed to the international variation observed. Some of the survey responses were “optional,” therefore creating variable denominators. These survey results particularly focused on V3a and V3b disease in women without pelvic pain, and these findings should not necessarily be extrapolated to women with V3a/V3b disease who also have clinically significant VO-CPP. The survey did not identify the timing or frequency of outcome assessments, limiting the ability to assess postprocedural follow up. Lastly, the varied practice patterns identified may impact outcomes, but we have not gathered any evidence to support this. Conclusions This international survey demonstrates marked heterogeneity in the evaluation, classification, and management of women with V3a and V3b PeVD. Diagnostic imaging strategies, use of standardized clinical and outcome measures, and treatment sequencing vary widely, with an almost even split between clinicians favoring pelvic embolization first and those treating extrapelvic varices first in the absence of pelvic pain. Similarly, no consensus exists regarding the management when iliac vein compression and ovarian vein reflux coexist or when symptoms persist after intervention. These findings underscore the need for standardized diagnostic algorithms for those with VO-CPP, uniform outcome reporting, and prospective comparative studies to better define optimal treatment strategies for patients with V3a and V3b disease. The marked variation observed reflects that this clinical area is in an early but pivotal stage lacking consensus regarding optimal evaluation/management. A required core outcome set and prospective trials are necessary to improve the evidence strength to optimize care. Author Contributions Conception and design: PC, KS, RW, NK Analysis and interpretation: PC, KS, RW, NK Data collection: PC, KS, RW, NK Writing the article: PC, KS, RW, NK Critical revision of the article: PC, KS, RW, NK Final approval of the article: PC, KS, RW, NK Statistical analysis: Not applicable Obtained funding: Not applicable Overall responsibility: PC Funding None. Disclosures K.S. serves as a speaker and consultant for Penumbra. N.K. serves as a speaker for Medtronic and Boston Scientific, a consultant for Boston Scientific, and a grant recipient from the Society of Interventional Radiology. P.C. and R.W. have no conflicts to disclose.